Medtech Talk

Gelfand and Levin Share Lessons from Ardian’s Rise and Fall…and Rise Again. Would They Do It Again?


Listen Later

Howard Levin and Mark Gelfand, the principals of Coridea, return to the podcast to detail the trials and tribulations of Ardian. Ardian is one of the bigger #medtech #startup stories over the past two decades. In 2011, Medtronic agreed to pay $800 million upfront for this company that pushed the once crazy idea of ablating renal nerves to lower hypertension. Ardian had raised $70 million from a syndicate of blue chip investors after being forged in the Foundry incubator. VCs proudly shared that the earnouts for Ardian would push that price well over $1 billion. This was a HUGE win for Medtech when it desperately needed it. 

Three years later came the fall. A day before JP Morgan’s Healthcare Meeting in 2014, Medtronic announced early disappointing of SYMPLICITY HTN-3, a third and larger trial of Ardian’s renal denervation.  Medtronic revised the trial, running Spryal HTN on patients who didn’t take any medication for their hypertension – a contrast from the Symplicity trial where patients were taking an average of five medications. In these revised trials, renal denervation is performing much better. 

The new results exonerated Ardian’s early backers – and perhaps Gelfand and Levin, specifically. This was the team, after all, that combed through medical libraries for clues about hacking the human body to beat back hypertension. The research turned up the discovery that surgeons once would treat extremely unresponsive hypertension by severing nerves near the kidney. 

The procedure worked, but it was dangerous. Levin and Gelfand saw ablating tissue as a safer path. And, after a lot of trudging up and down the Valley, finally found a willing partner in the team at The Foundry. Early clinical success led to a renal denervation gold rush. Nearly every VC and Strategic investor had a bet in this space.  

The 2014 debacle convinced many to close their programs and companies, but now Renal Denervation is back in favor.  

How did Howard Levin and Mark Gelfand enjoy the roller coaster ride? 

In this podcast, we’ll talk about Ardian, TAVR, the challenges facing Medtech VCs and the poor reception many surgeons give new interventional technologies.

...more
View all episodesView all episodes
Download on the App Store

Medtech TalkBy Healthegy

  • 4.8
  • 4.8
  • 4.8
  • 4.8
  • 4.8

4.8

57 ratings


More shows like Medtech Talk

View all
Wait Wait... Don't Tell Me! by NPR

Wait Wait... Don't Tell Me!

38,635 Listeners

Radiolab by WNYC Studios

Radiolab

43,935 Listeners

Monday Morning Podcast by All Things Comedy

Monday Morning Podcast

31,991 Listeners

DeviceTalks Podcast Network by DeviceTalks Podcast Network

DeviceTalks Podcast Network

47 Listeners

Global Medical Device Podcast powered by Greenlight Guru by Greenlight Guru + Medical Device Entrepreneurs

Global Medical Device Podcast powered by Greenlight Guru

91 Listeners

Pardon My Take by Barstool Sports

Pardon My Take

81,779 Listeners

How I Built This with Guy Raz by Guy Raz | Wondery

How I Built This with Guy Raz

30,217 Listeners

The Daily by The New York Times

The Daily

111,441 Listeners

Capital Allocators – Inside the Institutional Investment Industry by Ted Seides – Allocator and Asset Management Expert

Capital Allocators – Inside the Institutional Investment Industry

802 Listeners

All-In with Chamath, Jason, Sacks & Friedberg by All-In Podcast, LLC

All-In with Chamath, Jason, Sacks & Friedberg

9,040 Listeners

The Ezra Klein Show by New York Times Opinion

The Ezra Klein Show

15,216 Listeners

This Day in AI Podcast by Michael Sharkey, Chris Sharkey

This Day in AI Podcast

200 Listeners